"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets": Reply
- PMID: 37739593
- DOI: 10.1016/j.jtha.2023.07.029
"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets": Reply
Conflict of interest statement
Declaration of competing interests J.T. received honoraria from Roche, Octapharma, Takeda, Grifols, Novo Nordisk, and Sobi pharmaceuticals. J.M. received grant/research support from Biomarin, Norvatis, Novo Nordisk, Pfizer, Roche, Sanofi, Spark, UniQure; was a consultant/on the scientific board for Biomarin, Novo Nordisk, Roche, Takeda, Sanofi, and Spark; and participated in the Speaker bureau of ISTH, Novo Nordisk, Pfizer, Roche, Sanofi, Takeda, and WFH. J.C. and M.S. have no competing interests to disclose.
Comment on
-
Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets.J Thromb Haemost. 2023 Jul;21(7):1737-1740. doi: 10.1016/j.jtha.2023.03.016. Epub 2023 Mar 25. J Thromb Haemost. 2023. PMID: 36972786 Review.
-
"Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets": comment.J Thromb Haemost. 2023 Oct;21(10):2977-2979. doi: 10.1016/j.jtha.2023.07.026. J Thromb Haemost. 2023. PMID: 37739592 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
